JP2019512542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512542A5 JP2019512542A5 JP2018567022A JP2018567022A JP2019512542A5 JP 2019512542 A5 JP2019512542 A5 JP 2019512542A5 JP 2018567022 A JP2018567022 A JP 2018567022A JP 2018567022 A JP2018567022 A JP 2018567022A JP 2019512542 A5 JP2019512542 A5 JP 2019512542A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- values
- xrpd pattern
- crystalline form
- characteristic peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 86
- 239000013078 crystal Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 34
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims description 3
- 229940080277 cholesteryl sulfate Drugs 0.000 claims description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 3
- 150000003891 oxalate salts Chemical class 0.000 claims description 3
- 125000005490 tosylate group Chemical class 0.000 claims description 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003890 succinate salts Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307095P | 2016-03-11 | 2016-03-11 | |
| US62/307,095 | 2016-03-11 | ||
| PCT/US2017/021790 WO2017156403A1 (en) | 2016-03-11 | 2017-03-10 | Crystalline salt forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512542A JP2019512542A (ja) | 2019-05-16 |
| JP2019512542A5 true JP2019512542A5 (https=) | 2020-03-26 |
| JP7038675B2 JP7038675B2 (ja) | 2022-03-18 |
Family
ID=59789873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567022A Active JP7038675B2 (ja) | 2016-03-11 | 2017-03-10 | 結晶塩形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10683326B2 (https=) |
| EP (1) | EP3426675B1 (https=) |
| JP (1) | JP7038675B2 (https=) |
| CN (2) | CN115160402A (https=) |
| CA (1) | CA3017359A1 (https=) |
| WO (1) | WO2017156403A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3017359A1 (en) | 2016-03-11 | 2017-09-14 | Scott M. Duncan | Crystalline salt forms |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| KR20250010134A (ko) | 2018-04-02 | 2025-01-20 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 엘라미프레티드의 합성에 유용한 결정질 디펩티드 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG64368A1 (en) | 1988-06-30 | 1999-04-27 | Astra Ab | Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same |
| EP1599216B9 (en) | 2003-02-04 | 2015-02-11 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
| US20120178762A1 (en) * | 2006-12-15 | 2012-07-12 | Warner Chilcott Company, Llc | Compositions of azimilide dihydrochloride |
| US20100331265A1 (en) * | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
| US8586598B2 (en) | 2009-04-29 | 2013-11-19 | Nerviano Medical Sciences S.R.L. | CDK inhibitor salts |
| ES2964555T3 (es) | 2009-08-24 | 2024-04-08 | Stealth Biotherapeutics Inc | Péptido para uso en la prevención o tratamiento de la degeneración macular |
| EP3090754A1 (en) * | 2009-12-31 | 2016-11-09 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| CA2787331A1 (en) * | 2010-01-25 | 2011-07-28 | Hazel H. Szeto | Aromatic-cationic peptides and uses of same |
| EP3375449A1 (en) * | 2010-03-15 | 2018-09-19 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| WO2011156473A1 (en) | 2010-06-09 | 2011-12-15 | Abbott Laboratories | Crystalline forms of kinase inhibitors |
| CN104244964A (zh) * | 2012-02-22 | 2014-12-24 | 康肽德生物医药技术有限公司 | 用于预防或治疗眼科病状的方法和组合物 |
| ES2755134T3 (es) * | 2013-03-01 | 2020-04-21 | Stealth Biotherapeutics Corp | Métodos para el tratamiento de enfermedad mitocondrial |
| JP2016539931A (ja) * | 2013-10-23 | 2016-12-22 | 株式会社カネカ | テトラペプチド化合物及びその製造方法 |
| WO2015084649A1 (en) | 2013-12-03 | 2015-06-11 | Amgen Inc. | Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof |
| WO2016001042A1 (en) * | 2014-06-30 | 2016-01-07 | Flamma S.P.A. | Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide |
| WO2016004067A1 (en) * | 2014-06-30 | 2016-01-07 | Stealth Biotherapeutics Corp | Aromatic-cationic peptide formulations, compositions and methods of use |
| WO2016007921A1 (en) * | 2014-07-10 | 2016-01-14 | Rhodel Island Hospital | Treating arrhythmia with mitochondrial-targeted antioxidants |
| EP3265109B1 (en) | 2015-03-06 | 2020-10-21 | Stealth BioTherapeutics Corp | Processes for preparing pharmaceutically relevant peptides |
| CA3017359A1 (en) | 2016-03-11 | 2017-09-14 | Scott M. Duncan | Crystalline salt forms |
| EP3500286A4 (en) * | 2016-08-16 | 2020-03-25 | Stealth BioTherapeutics Corp | N-CARBOXYANHYDRIDE-BASED SCALE SYNTHESIS OF ELAMIPRETID |
| US11034724B2 (en) * | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) * | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| KR20250010134A (ko) * | 2018-04-02 | 2025-01-20 | 스텔스 바이오테라퓨틱스 인코포레이티드 | 엘라미프레티드의 합성에 유용한 결정질 디펩티드 |
-
2017
- 2017-03-10 CA CA3017359A patent/CA3017359A1/en active Pending
- 2017-03-10 EP EP17764188.3A patent/EP3426675B1/en active Active
- 2017-03-10 US US16/084,168 patent/US10683326B2/en active Active
- 2017-03-10 CN CN202210620260.3A patent/CN115160402A/zh active Pending
- 2017-03-10 CN CN201780029335.8A patent/CN109476700A/zh active Pending
- 2017-03-10 WO PCT/US2017/021790 patent/WO2017156403A1/en not_active Ceased
- 2017-03-10 JP JP2018567022A patent/JP7038675B2/ja active Active
-
2020
- 2020-05-04 US US16/866,164 patent/US11555053B2/en active Active
-
2022
- 2022-12-02 US US18/074,151 patent/US12252553B2/en active Active
-
2025
- 2025-02-14 US US19/053,773 patent/US20260015385A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512542A5 (https=) | ||
| JP2018024682A5 (https=) | ||
| JP2021530565A5 (https=) | ||
| JP2014522388A5 (https=) | ||
| JP2015527363A5 (https=) | ||
| JP2018531941A5 (https=) | ||
| JP2013546173A5 (https=) | ||
| JP2013049690A5 (https=) | ||
| JP2022511800A5 (https=) | ||
| HRP20200849T1 (hr) | Postupci razdvajanja dijastereoizomera gemcitabin-fosfata | |
| JP2016000739A5 (https=) | ||
| WO2016016766A3 (en) | A process for the preparation of isavuconazonium or its salt thereof | |
| JP2017501141A5 (https=) | ||
| JP2009179634A5 (https=) | ||
| WO2016038628A3 (en) | A process for preparing olodaterol and intermediates thereof | |
| JP2013520488A5 (https=) | ||
| CN111386268A (zh) | 一种urat1抑制剂的晶型及其制备方法 | |
| JP2019529481A5 (https=) | ||
| JP2015518469A5 (https=) | ||
| FR3028864B1 (fr) | Procede de recuperation de cristaux d'acide succinique avec mise en œuvre de tensioactifs au cours de la cristallisation, cristaux obtenus et leurs utilisations | |
| RU2019138773A (ru) | Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций | |
| JP2020502077A5 (https=) | ||
| HRP20170023T1 (hr) | Kristalni oblik pemirolasta | |
| JP2015514779A5 (https=) | ||
| HK1206747A1 (en) | Crystalline forms of an hcv inhibitor |